Capricor Therapeutics (CAPR) News Today $8.26 -3.68 (-30.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.24 -0.02 (-0.18%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Capricor Therapeutics stock plunges after key FDA officials placed on leaveJune 20 at 4:59 PM | in.investing.comCapricor falls after report on AdCom meeting cancellation (update)June 20 at 4:59 PM | msn.comCapricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel DataJune 20 at 4:59 PM | msn.comCapricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne PatientsJune 20 at 3:11 PM | benzinga.comCapricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular DystrophyJune 20 at 9:25 AM | globenewswire.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Buy" from BrokeragesShares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have earned an average rating of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year priceJune 19 at 4:26 AM | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from Roth CapitalJune 19 at 1:57 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 18 at 12:30 PM | globenewswire.comCapricor gets FDA's Orphan Drug status for muscle disorder therapyJune 17, 2025 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 6.8% - Still a Buy?Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 6.8% - Still a Buy?June 17, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at Roth CapitalRoth Capital reaffirmed a "buy" rating and set a $31.00 price objective on shares of Capricor Therapeutics in a report on Tuesday.June 17, 2025 | marketbeat.comDecoding Capricor Therapeutics's Options Activity: What's the Big Picture?June 17, 2025 | benzinga.comCapricor Therapeutics' Becker Muscular Dystrophy Drug Gets Orphan Drug Designation in U.S.June 17, 2025 | marketwatch.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 17, 2025 | prnewswire.comCapricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy ProgramJune 17, 2025 | globenewswire.comCapricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw unusually large options trading on Friday. Traders bought 7,897 put options on the stock. This represents an increase of 62% compared to the average daily volume of 4,879 put options.June 13, 2025 | marketbeat.comCapricor Therapeutics' (CAPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Friday.June 13, 2025 | marketbeat.comCapricor says FDA inspection brought Form 483 with several observationsJune 12, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 12, 2025 | prnewswire.comCalifornia State Teachers Retirement System Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR)California State Teachers Retirement System grew its position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 1,653.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,237 sJune 12, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $462,000 Position in Capricor Therapeutics Inc (NASDAQ:CAPR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchasedJune 12, 2025 | marketbeat.comCapricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel AdvancementJune 11, 2025 | seekingalpha.comFDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’June 11, 2025 | msn.comCapricor Therapeutics stock falls after FDA inspection of manufacturing facilityJune 11, 2025 | in.investing.comCapricor falls after facility inspection related to deramiocelJune 11, 2025 | msn.comCapricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy ProgramJune 11, 2025 | globenewswire.comCantor Fitzgerald Estimates CAPR FY2026 EarningsJune 11, 2025 | americanbankingnews.comBehind the Scenes of Capricor Therapeutics's Latest Options TrendsJune 11, 2025 | benzinga.comAnalysts Issue Forecasts for CAPR FY2026 EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Capricor Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecJune 10, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Down 6.8% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.8% - Should You Sell?June 9, 2025 | marketbeat.comWellington Management Group LLP Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR)Wellington Management Group LLP acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 40,959 shares of the biotechnology company's stock, valuedJune 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 6, 2025 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Time to Sell?June 4, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5% - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Trading Up 5% - Here's What HappenedJune 4, 2025 | marketbeat.comStock Traders Buy High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 6,025 call options on the stock. This represents an increase of approximately 44% compared to the average daily volume of 4,190 call options.June 4, 2025 | marketbeat.comTwo Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)Two Sigma Investments LP boosted its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 223.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,047 shares of tJune 3, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by Nuveen Asset Management LLCNuveen Asset Management LLC grew its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 392.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 169,111 shares of the biotechnology company's stock after acJune 3, 2025 | marketbeat.comBank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Bank of America Corp DE boosted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 938.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 170,543 shares of the biotechnology comJune 3, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 2, 2025 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest UpdateCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totalling 13,780,000 shares, an increase of 33.3% from the April 30th total of 10,340,000 shares. Approximately 34.4% of the company's stock are sold short. Based on an average trading volume of 2,050,000 shares, the days-to-cover ratio is currently 6.7 days.June 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 1, 2025 | prnewswire.comDeutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR)Deutsche Bank AG acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,877 shares of the biotechnology company's stock,June 1, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires New Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)Voloridge Investment Management LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 121,623 shares of the biotechnology compaMay 30, 2025 | marketbeat.comCapricor Therapeutics Announces Equity Incentive PlanMay 29, 2025 | uk.investing.comCapricor Therapeutics Announces Equity Incentive PlanMay 29, 2025 | uk.investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 26, 2025 | prnewswire.comD. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR)D. E. Shaw & Co. Inc. purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 53,734 shares of the biotechnology company's stMay 26, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by AnalystsShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objectiMay 26, 2025 | marketbeat.comWoodline Partners LP Invests $8.69 Million in Capricor Therapeutics Inc (NASDAQ:CAPR)Woodline Partners LP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 629,934 shares of the biotechnology company's stMay 25, 2025 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.170.66▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼186▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LGND News Today NAMS News Today BHC News Today ARWR News Today KNSA News Today AGIO News Today SRPT News Today IDYA News Today INDV News Today BLTE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
